CD79A and rheumatoid arthritis: The results demonstrated that prolonged XFC treatment was associated with progressively greater improvements in ESR, Hs-CRP, RF, CCP, IgA, IgG, IgM, C3, and C4 levels (Figure 1C), indicating a sustained therapeutic effect on immunoinflammatory responses in RA patients.